Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Eric Davis

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
Cancer Immunology Research|September 12, 2020
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic PhenotypeAshvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, et al.
Leukemia|March 28, 2018
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myelomaXiaohui Zhang, Hans C Lee, Fazal Shirazi, et al.
JCI Insight|July 7, 2017
AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growthV Lokesh Battula, Phuong M Le, Jeffrey C Sun, et al.
Leukemia & Lymphoma|January 24, 2020
Pretreatment SUV<sub>max</sub> may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2007
Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activationYuli Xie, ShiXian Deng, Craig J Thomas, et al.
The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.
Science (New York, N.Y.)|March 8, 2008
Oncogenic CARD11 mutations in human diffuse large B cell lymphomaGeorg Lenz, R Eric Davis, Vu N Ngo, et al.
Blood Cancer Journal|July 2, 2026
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphomaKaran L Chohan, Eduardo Edelman Saul, R Eric Davis, et al.
Blood Advances|November 14, 2022
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCLHua-Jay J Cherng, Stefan K Alig, Yasuhiro Oki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia ModelsJuliana Benito, Marc S Ramirez, Niki Zacharias Millward, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Cancer Immunology Research|September 12, 2020
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic PhenotypeAshvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, et al.
Leukemia|March 28, 2018
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myelomaXiaohui Zhang, Hans C Lee, Fazal Shirazi, et al.
JCI Insight|July 7, 2017
AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growthV Lokesh Battula, Phuong M Le, Jeffrey C Sun, et al.
Leukemia & Lymphoma|January 24, 2020
Pretreatment SUV<sub>max</sub> may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2007
Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activationYuli Xie, ShiXian Deng, Craig J Thomas, et al.
The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.
Science (New York, N.Y.)|March 8, 2008
Oncogenic CARD11 mutations in human diffuse large B cell lymphomaGeorg Lenz, R Eric Davis, Vu N Ngo, et al.
Blood Cancer Journal|July 2, 2026
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphomaKaran L Chohan, Eduardo Edelman Saul, R Eric Davis, et al.
Blood Advances|November 14, 2022
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCLHua-Jay J Cherng, Stefan K Alig, Yasuhiro Oki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia ModelsJuliana Benito, Marc S Ramirez, Niki Zacharias Millward, et al.
Pageof 9